This is a preview of subscription content, log in via an institution to check access. Access this article Log in via an institution Subscribe and save Springer+ from €39.99 /Month Starting from 10 chapters or articles per month Access and...
The primary systemic treatment for advanced colorectal cancer (CRC) is chemotherapy, but inevitable drug resistance leads to poor prognosis. Cancer stem cells (CSCs) are recognized as significant contributors to chemotherapy resistance, yet the mechanisms underlying their ability to induce widespread...
AbstractPurpose Type 1 diabetes mellitus (T1DM) results from autoimmune-mediated destruction of pancreatic β-cells, leading to absolute insulin deficiency. Current treatments rely on insulin replacement and do not prevent β-cell loss. 4-Methylumbelliferone (4-MU), an inhibitor of hyaluronan synthesis, has shown anti-inflammatory...
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), has shown remarkable efficacy in EGFR-mutant non-small cell lung cancer (NSCLC). However, acquired resistance remains inevitable. This study aimed to explore the underlying resistance mechanisms and evaluate second-line treatment strategies to improve...
BackgroundThe PACIFIC regimen (consolidation durvalumab following chemoradiotherapy) is the standard of care for unresectable stage III non-small cell lung c Abstract Background: The PACIFIC regimen (consolidation durvalumab following chemoradiotherapy) is the standard of care for unresectable stage III non-small cell...
AbstractPurpose Leptomeningeal metastasis (LM) carries a poor prognosis in EGFR-mutant non-small cell lung cancer (NSCLC). This study aims to explore clinical features and survival outcomes and develop a nomogram for overall survival (OS) in this population. Methods We retrospectively enrolled...
AbstractPurpose Ramucirumab plus FOLFIRI is an established second-line treatment option for metastatic colorectal cancer (mCRC) after oxaliplatin-based first-line therapy. However, real-world data comparing outcomes according to prior biologic exposure are limited. Methods We retrospectively reviewed patients with mCRC who received...
AbstractBackground To develop and validate a contrast-enhanced ultrasound (CEUS)-based habitat model for noninvasive prediction of epidermal growth factor receptor (EGFR) mutation status in patients with peripheral non-small cell lung cancer (NSCLC). Methods This retrospective study included 187 patients with NSCLC...
Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as...
Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as...
